Regeneron Pharmaceuticals, Inc. (REGN)
Fuera de horario:
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13,450
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 8.18M | N/D | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 7.76M | N/D | 1960 |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1.68M | 21.37M | 1959 |
| Dr. John Lin | Senior VP of Immuno-Oncology & Head of Bispecifics | N/D | N/D | N/D |
| Dr. Hanne Bak | Senior Vice President of Preclinical Manufacturing & Process Development | N/D | N/D | N/D |
| Dr. Aris Baras M.D. | Senior Vice President of Regeneron Genetics Center | N/D | N/D | N/D |
| Dr. Brian P. Zambrowicz Ph.D. | Executive VP of Functional Genomics & Chief VelociGene Operations | N/D | N/D | 1963 |
| Dr. Israel Lowy M.D., Ph.D. | Senior Vice President of Translational & Clinical Sciences - Oncology | N/D | N/D | N/D |
| Mr. Justin Holko | Senior Vice President of Global Oncology & Hematology Commercial Business Unit | N/D | N/D | N/D |
| Mr. Nouhad Husseini | Senior VP of Business Development & MD | N/D | N/D | N/D |
Descripción
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Regeneron Pharmaceuticals, Inc. a partir del 1 de abril de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 10; Compensación: 9.
